Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a Phase 1/2 open-label study to evaluate the safety and efficacy of Etentamig, a new investigational drug, for treating multiple myeloma. The study aims to assess changes in disease activity and adverse events in adult participants receiving Etentamig alone or in combination with other treatments like Daratumumab, Lenalidomide, and Carfilzomib. This research is significant as it targets relapsed or refractory multiple myeloma, a challenging condition to treat.
The intervention involves administering Etentamig as an intravenous infusion, either alone or in combination with other drugs. The goal is to determine the optimal dosing and effectiveness of Etentamig in managing multiple myeloma symptoms.
The study design is interventional, with a randomized allocation and a parallel intervention model. It is an open-label study, meaning no masking is involved, and the primary purpose is treatment-focused.
The study began on June 30, 2025, with an estimated completion timeline of approximately 130 months. The latest update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and potential market entry of Etentamig.
The outcome of this study could significantly impact AbbVie’s stock performance and investor sentiment, especially if Etentamig proves effective. As the pharmaceutical industry remains competitive, successful results could position AbbVie favorably against its peers.
The study is ongoing, with further details available on the ClinicalTrials portal.